Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.34 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31325021 | 0.84 | NLRP3 (0.49) | NLRP3TSHRTLR9TLR8TLR7 | |
| SCHEMBL24834533 | 0.82 | ALOX15 (0.54) | ALOX15RAB9ATSHRCMA1 | |
| SCHEMBL31325017 | 0.81 | NLRP3 (0.62) | NLRP3 | |
| SCHEMBL31325029 | 0.81 | NLRP3 (0.43) | NLRP3TSHRTLR9TLR8TLR7 | |
| SCHEMBL25949976 | 0.81 | NLRP3 (0.43) | NLRP3TSHRTLR9TLR8TLR7 | |
| SCHEMBL31325024 | 0.80 | NLRP3 (0.40) | NLRP3RAB9A | |
| SCHEMBL25949963 | 0.80 | NLRP3 (0.40) | NLRP3RAB9A | |
| SCHEMBL24077178 | 0.79 | NLRP3 (0.46) | NLRP3ALOX15RAB9ATSHRCMA1 | |
| SCHEMBL24834518 | 0.78 | NLRP3 (0.44) | NLRP3ALOX15RAB9ATSHRCMA1 | |
| SCHEMBL30169673 | 0.78 | NLRP3 (0.44) | NLRP3ALOX15RAB9ATSHRCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066369-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NodThera Limited (GB) | 2025-02-27 | — | — | US | disclosed |
| EP-4460505-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | Nodthera Limited (GB) | 2024-11-13 | — | — | EP | disclosed |
| CN-118922421-A | Bicyclic phthalazin-1 (2H) -one derivatives and related uses | 诺瑟拉有限公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2023133271-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NodThera Limited (GB) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133271-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NodThera Limited (GB) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066369-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | IL1B, NLRP3, IL1A | NLRP3 2/4885ALOX15 257/4885PPARA 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.